Please enable Javascript
Toni Choueiri, MD
Articles by Toni Choueiri, MD
What’s Next for RCC Treatment? Promising New Targets and Clinical Trials
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
December 30, 2024
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
View More
The Future of RCC Treatment Sequencing and Individualized Patient Care
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
December 30, 2024
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
View More
Navigating Treatment Sequencing and Toxicity in RCC: Insights From TiNivo-2
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
December 30, 2024
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
View More
TiNivo-2 Efficacy: Breaking Down the Data on TKI and Immunotherapy in RCC Treatment
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
December 30, 2024
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
View More
TiNivo-2 vs CONTACT-03: Trial Design and Key Differences
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
December 30, 2024
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 4: What About CTLA-4-Based Salvage After IO in RCC?
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 30, 2024
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 3: IO Therapy After Adjuvant Pembrolizumab?
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 30, 2024
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 2: Do We Need a Post-Adjuvant Pembrolizumab Study?
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 29, 2024
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 1: CONTACT-03, TiNivo-2 Study Results and Implications
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 29, 2024
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
View More
Capturing the Rapidly Evolving Landscape of Advanced GU Cancers: AUC3
Toni Choueiri, MD
AUC3
|
October 15, 2024
Dr. Choueiri outlines the importance of experts putting their heads together to decide on how to approach gray areas.
View More
The Uromigos' Definition of Oligometastatic: Live Session From The Uromigos Live & Unplugged 2024
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 2, 2024
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
View More
IO Rechallenge: Live Session From The Uromigos Live & Unplugged 2024
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 2, 2024
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
View More
First-of-Its-Kind Interactive Decision-Making
Toni Choueiri, MD
AUC3
|
September 20, 2024
Dr. Toni Choueiri looks forward to the interactive aspect of AUC3 for better decision-making in urologic cancers.
View More